Suchergebnisse - "Voorhees, Peter"

PubPharm (21)

1

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

2

A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Bhutani, M. | Foureau, D. | Robinson, M. | +14

3

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma : Analysis of vascular thrombotic events in the GRIFFIN study

enthalten in: British journal of haematology | 2022

von Sborov, D. | Baljevic, M. | Reeves, B. | +18

4

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

enthalten in: American journal of hematology | 2021

von Voorhees, P. | Suman, V. | Tuchman, S. | +9

5

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma : long-term survival follow-up from the Phase II study O-12-M1

enthalten in: British journal of haematology | 2021

von Bringhen, S. | Voorhees, P. | Plesner, T. | +8

6

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211) : primary analysis of a randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2021

von Usmani, S. | Hoering, A. | Ailawadhi, S. | +15

CommentIn: Lancet Haematol. 2021 Jan;8(1):e4-e6. - PMID 33357481

7

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma : analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

enthalten in: Blood cancer journal | 2020

von Richardson, P. | Lee, H. | Abdallah, A. | +13

8

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma : the GRIFFIN trial

enthalten in: Blood | 2020

von Voorhees, P. | Kaufman, J. | Laubach, J. | +26

CommentIn: Blood. 2020 Aug 20;136(8):917-918. - PMID 32818244

9

Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Ailawadhi, S. | Sexton, R. | Lentzsch, S. | +11

10

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma : a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

enthalten in: Leukemia | 2020

von Landgren, C. | Chari, A. | Cohen, Y. | +18